Windtree Therapeutics

Windtree Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Windtree Therapeutics (WINT) as of Oct 19, 2026 is -25.02 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -17.54 M USD — a change of 42.65% (lower).

EBITDA

-25.02 MUSD

YoY

42.65%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Windtree Therapeutics is 2024 -25.02 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Windtree Therapeutics was 2023 -17.54 M USD. It decreases by 42.65% lower compared to the previous year.

The Windtree Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-22.55 M USD
Jan 1, 2018
-19.14 M USD
Jan 1, 2019
-26.98 M USD
Jan 1, 2020
-32.44 M USD
Jan 1, 2021
-77.51 M USD
Jan 1, 2022
-41.33 M USD
Jan 1, 2023
-17.54 M USD
Jan 1, 2024
-25.02 M USD
The Windtree Therapeutics EBITDA history
YEAREBITDAYoY
-25.02 MUSD+42.65%
-17.54 MUSD-57.57%
-41.33 MUSD-46.67%
-77.51 MUSD+138.92%
-32.44 MUSD+20.24%
-26.98 MUSD+40.97%
-19.14 MUSD-15.12%
-22.55 MUSD-39.04%
-36.99 MUSD-7.14%
-39.83 MUSD-7.92%
-43.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Windtree Therapeutics Stock analysis

What does Windtree Therapeutics do? Windtree Therapeutics Inc., based in Warrington, Pennsylvania, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures KL4 surfactant therapies for respiratory diseases, focusing on respiratory distress syndrome in premature infants. Its core product, AEROSURF (lucinactant for inhalation), targets non-invasive treatment of respiratory conditions. Windtree employs 14 full-time staff and is listed on the stock market since 1995. Windtree Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Windtree Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Windtree Therapeutics is -25.02 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Windtree Therapeutics changed from -17.54 M USD to -25.02 M USD, representing a 42.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Windtree Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Windtree Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Windtree Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Windtree Therapeutics